Infliximab, subcutaneous anti-TNF agents, and ustekinumab show comparable effectiveness as second-line therapies in patients with ulcerative colitis after vedolizumab failure.

In children hospitalised with acute severe ulcerative colitis on intravenous corticosteroids, intestinal ultrasound (IUS) parameters such as colonic wall thickness (CWT) were associated with ...

A groundbreaking discovery in modernizing traditional Chinese medicine (TCM) has been achieved. A study has, for the first ...

WILMINGTON, Del., April 2, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced the first patient has been dosed in a Phase IIa ...

Medications are the foundation of treatment for moderate to severe ulcerative colitis (UC), with advanced therapies like JAK inhibitors, immunosuppressants, and biologics often playing a key role in ...

For people with UC, ‘feeling better’ is just the start. Learn why tissue-level (histological) healing is becoming the new gold standard for UC remission and cancer prevention.

The human monoclonal antibody guselkumab has been approved for certain adults with moderately to severely active ulcerative colitis since April 2025 ...

Investing.com - Roth/MKM initiated coverage on Equillium Inc. (NASDAQ:EQ) with a buy rating and a price target of $12.00, citing the company’s experimental ulcerative colitis treatment. The stock has ...

Inflammatory bowel disease (IBD) patients may benefit from vitamin D, which helps rebalance immune responses to gut bacteria, and support gut health.

CAR-T cell therapy, originally developed for cancer, is showing ever more promise as a treatment for autoimmune diseases.